KalVista Pharmaceuticals, Inc. Q3 2025 Earnings Recap

KALV Q3 2025 November 12, 2025

Get alerts when KALV reports next quarter

KalVista Pharmaceuticals delivered a positive third quarter, demonstrating steady adoption of EKTERLY and expanding its global footprint with multiple regulatory approvals, positioning the company well for growth in the HAE treatment landscape.

Earnings Per Share Beat

$-0.92 vs $-0.96 est.

+4.2% surprise

Revenue Miss

13692000 vs 32285710 est.

-57.6% surprise

Market Reaction

1-Day -1.87%

5-Day +2.77%

30-Day +26.69%

See KALV alongside your other holdings

Add to your portfolio — free

Key Takeaways

EKTERLY adoption in the U.S. is strong, with utilization aligned with expectations for treating HAE attacks.
Successful launch in Germany and recent approval in Australia, contributing to an expanding international market presence.
KONFIDENT-KID trial confirms high treatment satisfaction and rapid symptom relief in pediatric patients aged 2 to 11, with plans for an NDA submission in Q3 2026.
Recent data showcases a decline in the need for injectable treatments, indicating growing patient confidence in EKTERLY.
Company is fully financed through profitability following a successful convertible note offering, allowing focus on EKTERLY’s launch and strategic growth opportunities.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KALV on AllInvestView.